To further assess performance across intrinsic molecular subtypes, we stratified the TCGA cohort into luminal A (n = 306), luminal B (n = 76), triple-negative breast cancer (TNBC, n = 98), and HER2+ (n = 35) subgroups. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.